BG Medicine, Inc.

FDA's Accomplishments in 2005 Highlight BG Medicine's Role in Liver Toxicology Biomarker Study

FDA's Accomplishments in 2005 Highlight BG Medicine's Role in Liver Toxicology Biomarker Study

March 29, 2006

In its recent report on accomplishments during this last year, the FDA highlighted their agreement in October of 2005 with Flagship portfolio company BG Medicine as an important example of their Critical Path initiative. You can read more about the project on its website.

Full text of the FDA's press release follows:

FDA's Accomplishments in 2005

Zalicus

CombinatoRx Announces Discovery of Novel Synergistic Combination Leads for Glioblastoma

CombinatoRx Announces Discovery of Novel Synergistic Combination Leads for Glioblastoma

April 3, 2006

Data presented at AACR

Interactive Supercomputing Corporation

New Opteron-based Star-P Software Brings Supercomputing to the Masses

New Opteron-based Star-P Software Brings Supercomputing to the Masses

April 17, 2006

ISC's interactive parallel computing platform to run on 64-bit AMD Opteron-based high performance computers

Doug Levinson Joins Flagship Ventures

Doug Levinson Joins Flagship Ventures

April 17, 2006


We are pleased to announce the recent addition of Doug Levinson, PhD, to the Flagship Ventures team as Partner. He brings to Flagship’s venture investment and new venture creation activities over fifteen years of experience in the biotech industry.

Zalicus

CombinatoRx Reports Positive Results for CRX-170 in Phase 2 Proof-of-Concept Asthma Clinical Trial

CombinatoRx Reports Positive Results for CRX-170 in Phase 2 Proof-of-Concept Asthma Clinical Trial

April 18, 2006

Novel Combination Drug Candidate Demonstrates Clinical Benefit on Forced Expiratory Volume (FEV1)

Acceleron Pharma, Inc.

Acceleron Pharma Appoints Matthew L. Sherman, M.D. as Chief Medical Officer

Acceleron Pharma Appoints Matthew L. Sherman, M.D. as Chief Medical Officer

May 16, 2006

Dr. Sherman's Expertise in Building a Clinical Development Organization and Advancing Programs Through Regulatory Approval a Key Addition to the Management Team

5/16/2006 - Acceleron Pharma, Inc., a biopharmaceutical company focused on developing and commercializing therapeutics based on its novel tissue growth factor platform, today announced the appointment of Matthew L. Sherman, M.D. as Senior Vice President and Chief Medical Officer.

Ensemble Therapeutics Corporation

Ensemble Discovery Appoints Nick Terrett, PhD as Chief Scientific Officer

Ensemble Discovery Appoints Nick Terrett, PhD as Chief Scientific Officer

May 22, 2006

 CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2006--Ensemble Discovery Corporation today announced the appointment of Nick Terrett, PhD to the newly created role of Chief Scientific Officer. In this capacity, Dr. Terrett will oversee all of Ensemble Discovery's pharmaceutical research and development activities.

Zalicus

CombinatoRx Reports Second Positive Phase 2 Study with CRx-102

CombinatoRx Reports Second Positive Phase 2 Study with CRx-102

May 22, 2006

Achieved Primary Endpoint with Statistically Significant Reduction in C-Reactive Protein in Human Inflammatory Model

Helicos BioSciences Corporation

Helicos BioSciences Announces First "Early Access" Partnership with Institute for Systems Biology

Helicos BioSciences Announces First "Early Access" Partnership with Institute for Systems Biology

June 7, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 7, 2006--Helicos BioSciences, a pioneer in high-speed, high-sensitivity sequencing, today announced a new partnership with the Institute for Systems Biology (ISB) as the company's first "Early Access" program research collaborator. The ISB is an internationally renowned non-profit research institute dedicated to the study and application of systems biology. The partnership will allow the ISB access to Helicos' True Single Molecule Sequencing (tSMS(TM)) technology and protocols for use in its scientifically groundbreaking research projects.

Morphotek, Inc.

Morphotek Announces Initiation of Phase II Clinical Studies For MORAb-003 in Ovarian Cancer

Morphotek Announces Initiation of Phase II Clinical Studies For MORAb-003 in Ovarian Cancer

June 8, 2006

EXTON, Pa., June 8 /PRNewswire/ -- Morphotek, Inc. today announced initiation of Phase II efficacy studies in major cancer centers worldwide for its anti-cancer antibody MORAb-003. MORAb-003 is a monoclonal antibody that targets the folate receptor alpha (FRA), a target over-expressed in over 90% of ovarian cancers and a number of other solid tumors. The antibody works via suppression of FRA-mediated signal transduction and induces tumor-specific cytotoxicity by both antibody dependent cellular and complement mediated immune-effector mechanisms.